Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Empagliflozin preserves cardiac function and modulates metabolism in a mouse model of Duchenne muscular dystrophy
Benjamin J. Zeidler, Connor Thomas, John P. Salvas, Areli Jannes S. Javier, Alyssa M. Richards, Linda A. Bean, Conner C. Earl, Akanksha Agrawal, Niharika Narra, Steven N. Kozakiewicz, Lifan Zeng, Carol A Witczak, Joshua R Huot, Il-Man Kim, Meena S. Madhur, Mark C. Kowala, Larry W. Markham, Craig J. Goergen, Steven S. Welc
Benjamin J. Zeidler, Connor Thomas, John P. Salvas, Areli Jannes S. Javier, Alyssa M. Richards, Linda A. Bean, Conner C. Earl, Akanksha Agrawal, Niharika Narra, Steven N. Kozakiewicz, Lifan Zeng, Carol A Witczak, Joshua R Huot, Il-Man Kim, Meena S. Madhur, Mark C. Kowala, Larry W. Markham, Craig J. Goergen, Steven S. Welc
View: Text | PDF
Research In-Press Preview Cardiology Cell biology Muscle biology

Empagliflozin preserves cardiac function and modulates metabolism in a mouse model of Duchenne muscular dystrophy

  • Text
  • PDF
Abstract

Duchenne muscular dystrophy (DMD) is a fatal genetic disorder characterized by skeletal muscle degeneration and cardiomyopathy. Effective cardiac therapies remain limited. This study investigated the therapeutic potential of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMPA) in the dystrophin-deficient DBA2/J-mdx mouse model of DMD. Male mice received control chow or EMPA-containing chow (~25mg/kg/day), and cardiac function was evaluated longitudinally using four-dimensional ultrasound imaging. EMPA did not alter left ventricular mass or volume but delayed the onset of systolic dysfunction, preserving ejection fraction (EF) for 12 weeks and maintaining significantly higher EF through 24 weeks. EMPA also attenuated progressive impairments in systolic and diastolic myocardial deformation. Functional preservation was accompanied by reduced cardiomyocyte hypertrophy and reduced expression of cardiac stress genes. EMPA increased mtDNA copy number, reduced mtDNA damage, preserved the mtDNA-encoded respiratory chain protein MT-CO1, and increased myocardial ATP content, supporting improved mitochondrial integrity and myocardial energetic capacity. In addition, EMPA induced transcriptional changes consistent with enhanced fatty acid and ketone metabolism. Systemically, EMPA improved growth trajectory, preserved relative lean mass, increased skeletal muscle torque, attenuated fiber-type remodeling, and did not adversely affect renal function. Together, these findings support SGLT2 inhibitors as a promising therapeutic strategy for DMD-associated cardiomyopathy.

Authors

Benjamin J. Zeidler, Connor Thomas, John P. Salvas, Areli Jannes S. Javier, Alyssa M. Richards, Linda A. Bean, Conner C. Earl, Akanksha Agrawal, Niharika Narra, Steven N. Kozakiewicz, Lifan Zeng, Carol A Witczak, Joshua R Huot, Il-Man Kim, Meena S. Madhur, Mark C. Kowala, Larry W. Markham, Craig J. Goergen, Steven S. Welc

×

Full Text PDF


Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts